Sourasky Medical Center (Ichilov)
No hidden fees – just official clinic prices. Pay at the clinic for Nuclear medicine treatment upon arrival and use a flexible installment plan if needed.
Bookimed is committed to your safety. We only work with medical institutions that maintain high international standards in Nuclear medicine treatment and have the necessary licenses to serve international patients worldwide.
Bookimed offers free expert assistance. A personal medical coordinator supports you before, during, and after your treatment, solving any issues. You're never alone on your Nuclear medicine treatment journey.
Prof. Zvi Cohen is Director of the Neurosurgery Department and the Neuro-Oncology Unit at Sheba Medical Center. He is a neurosurgeon and neuro-oncology expert. He was included in Forbes Israel’s Best Doctors 2025. He leads clinical research on drug therapies for malignant brain tumors. He also founded Sheba’s brain tumor tissue bank.
He is board-certified in neurosurgery. He trained at Tel Aviv University. He completed fellowships in neuroradiology at Beth Israel and in neurosurgical oncology at MD Anderson. His practice covers complex brain, pituitary, spine, and spinal cord tumors. He has expertise in stereotactic biopsies, image-guided resections, intraoperative MRI, navigation systems, and radiosurgery. He is a member of the Society for Neuro-Oncology and the Israeli Association of Neurological Surgeons.
Dr. Einat Shacham‑Shmueli is a senior medical oncologist at the Gastrointestinal Clinic, Cancer Center, Sheba Medical Center. She treats cancers of the colon, stomach, and pancreas. She also manages metastatic disease. She uses precision diagnostics and biomarkers, systemic therapies, and radiotherapy. Care is provided within a multidisciplinary team.
She has authored more than 25 peer‑reviewed papers on GI oncology, tumor biology, and new treatments. Her work includes studies on stenting for malignant colonic obstruction. She serves as an investigator in international programs, including the NCI, the Radiation Therapy Oncology Group, and the Cancer Therapy Evaluation Program.
Education: MD, Tel Aviv University. Oncology residency, Tel Aviv Sourasky Medical Center. Advanced training in GI oncology, UCSF. Accreditations: Board certified in Oncology and Gastroenterology. Member, Israel Society of Oncology and Radiotherapy.
Dr. Yuri Goldes is a general surgeon with more than 20 years of clinical experience. He specializes in upper gastrointestinal and oncologic surgery. He is Deputy Director of the Department of General Surgery and Transplantation at Sheba Medical Center in Tel Aviv. He also leads the Upper GI Surgery Unit. He was named to Forbes Israel’s Best Doctors in 2025. He is ranked among Israel’s Best Gastrointestinal Surgeons by Forbes. In 2019, he received the Israeli Ministry of Health “Best Doctor of the Year” award.
He is an expert in advanced minimally invasive and robotic surgery. He treats diaphragmatic hernia, achalasia, GERD, and gallbladder disease. He also performs oncologic surgery for pancreatic, gastric, and esophageal cancers. He uses laparoscopic and robotic techniques.
He pioneered some of Israel’s first robotic oncologic resections of the stomach and pancreas. He is among a small group worldwide who perform minimally invasive Whipple procedures (pancreaticoduodenectomy) using advanced laparoscopy. He applies methods that improve outcomes and speed recovery. He provides personalized care.
Dr. Nir Kleinmann, MD, directs the Endourology and Kidney Stones Unit at Sheba Medical Center. He is an expert in minimally invasive urology and urologic oncology. His focus is the kidney and upper urinary tract. He was named among Israel’s Best Doctors for 2025–2026 by Forbes and ResultMed.
He is a pioneer of kidney‑sparing laser surgery. He uses a dual‑laser system with neodymium and holmium for complex tumors. His expertise includes UTUC, kidney and prostate cancer, kidney stones, and BPH.
His research includes the OLYMPUS trial on chemoablation for UTUC. He has more than 60 publications.
He is an Israeli board‑certified urologist. He is a Fellow of the American Endourology Society and a member of the Israeli Urological Association and the EAU. He completed fellowships in Endourology and Minimally Invasive Surgery at Thomas Jefferson University. He also completed a fellowship in Kidney Cancer Research at McMaster University.
Nuclear medicine in Israel treats oncological, endocrine, and inflammatory conditions. Specialized centers use radiopharmaceuticals like Lutetium-177 and Iodine-131. These therapies target prostate cancer, thyroid disorders, and neuroendocrine tumors. Facilities such as Sourasky Medical Center (Ichilov) provide these advanced molecular treatments to international patients.
Bookimed Expert Insight: Sourasky Medical Center (Ichilov) serves over 1,800,000 patients annually. Its scale allows doctors to pioneer new molecular protocols. Patients often find faster access to Lutetium-177 therapies here compared to other regions. This high volume translates into deep institutional expertise in complex radiopharmaceutical administration.
Patient Consensus: Patients report that Lutetium-177 therapy significantly improved their quality of life. Many note that these targeted treatments had fewer side effects than traditional chemotherapy. Those seeking Iodine-131 often mention that the isolation periods are shorter and more manageable than expected.
Nuclear medicine in Israel is exceptionally safe. It follows strict International Atomic Energy Agency (IAEA) protocols. Facilities use advanced PET-CT and SPECT-CT hybrid imaging. These technologies provide high-quality diagnostics with the lowest possible radiation doses. Centers like Sourasky Medical Center prioritize patient safety through rigorous international standards.
Bookimed Expert Insight: Our data shows that top Israeli centers like Sourasky Medical Center integrate digital imaging and AI directly into nuclear medicine workflows. This automation reduces human error in dosage calculations. Clinics with over 6,000 employees typically have more dedicated safety officers per department than smaller facilities. This infrastructure ensures that radiation protocols are followed more consistently during complex isotope treatments.
Patient Consensus: Patients note that the treatment process is very professional and organized. They emphasize that radiation levels are monitored closely and isolation rooms are kept remarkably clean.
Nuclear medicine uses internal radiopharmaceuticals to treat cancer systemically from within the body. Conventional radiation therapy employs external machines to aim high-energy beams at specific tumors. Israeli centers like Sourasky Medical Center (Ichilov) use these complementary methods to target both localized and metastatic diseases effectively.
Bookimed Expert Insight: Data from Sourasky Medical Center shows a 90% success rate for oncology treatments. This performance often stems from combining both modalities in a single facility. High-volume centers with over 1,500 beds can coordinate these complex therapies faster than smaller clinics. This integration reduces the total time patients spend in active treatment.
Patient Consensus: Patients note that nuclear medicine involves minimal pain during injections compared to external radiation. Many emphasize asking doctors how long isotopes stay in the body after treatment ends.
Radioactivity levels after procedures in Israel depend on the specific treatment type. Diagnostic scans like PET or bone scans leave you mildly radioactive for 24–48 hours. Internal therapies using isotopes like I-131 require stricter isolation for 3 to 14 days to protect others.
Bookimed Expert Insight: Israeli facilities like Sourasky Medical Center (Ichilov) manage over 1.8 million patient visits annually. Their high volume means protocols for post-procedure isolation are highly standardized. Our data shows these centers often coordinate local stay arrangements specifically designed for isotope therapy recovery. This ensures international patients meet safety rules before flying home.
Patient Consensus: Patients note that triggers at airport security can happen even weeks later. Many recommend keeping your medical discharge papers handy to explain any sensor alerts during travel. Others suggest using disposable utensils and sleeping alone for the first week to keep family safe.
Nuclear medicine studies in Israel typically require 2 to 6 hours from arrival to departure. Most results are finalized within 24 to 48 hours. Patients often access preliminary findings through online portals or apps sooner. Timing depends on the specific tracer uptake and scanning complexity.
Bookimed Expert Insight: Israeli medical centers like Sourasky Medical Center leverage advanced digital infrastructure for rapid results. Data shows that using the hospital's patient portal often provides access to findings faster than waiting for a doctor's call. This is especially useful for international patients traveling from Tel Aviv shortly after their diagnostic scans.
Patient Consensus: Patients note that the process is efficient but recommend bringing a book for the long waiting periods. Many emphasize that private facilities often provide quicker turnaround for results compared to public hospitals.
Preparation for a nuclear medicine test in Israel requires fasting for 4–6 hours for PET-CT or cardiac scans. Patients must avoid strenuous exercise for 48 hours before appointments. Major centers like Sourasky Medical Center (Ichilov) require warm, metal-free clothing and proper hydration to aid radiotracer circulation.
Bookimed Expert Insight: Sourasky Medical Center (Ichilov) treats over 400,000 patients annually and uses advanced digital imaging systems. Our data shows that high-volume Israeli centers often provide preparation materials in both Hebrew and English. Requesting these written guides early prevents common misunderstandings regarding specific medication pauses before complex scans.
Patient Consensus: Patients emphasize arriving 20 minutes early because parking at major Israeli hospitals is often difficult. They also recommend bringing a Hebrew-speaking friend to smaller clinics where English-speaking staff might be limited.